Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 7/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MLYCD | O95822 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2655426 | 0.96 | KMT2A (0.73) | KMT2AMEN1HSD11B1SMN1; SMN2HPGD | |
| SCHEMBL29944147 | 0.95 | MEN1 (0.71) | KMT2AMEN1HSD11B1SMN1; SMN2HPGD | |
| SCHEMBL2004712 | 0.86 | KMT2A (0.69) | KMT2AMEN1HSD11B1SMN1; SMN2HPGD | |
| SCHEMBL24746291 | 0.84 | HPGD (0.58) | KMT2AMEN1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL21962176 | 0.84 | SMN1; SMN2 (0.55) | KMT2AMEN1HSD11B1SMN1; SMN2HPGD | |
| SCHEMBL27986249 | 0.84 | KMT2A (0.67) | KMT2AMEN1HSD11B1HPGDALDH1A1 | |
| SCHEMBL19088583 | 0.84 | HPGD (0.62) | KMT2AMEN1HSD11B1SMN1; SMN2HPGD | |
| SCHEMBL22053135 | 0.84 | HPGD (0.58) | KMT2AMEN1HSD11B1SMN1; SMN2HPGD | |
| SCHEMBL2075037 | 0.84 | HPGD (0.68) | KMT2AMEN1HSD11B1SMN1; SMN2HPGD | |
| SCHEMBL30545431 | 0.83 | KMT2A (0.65) | KMT2AMEN1HSD11B1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| CN-102015637-B | Phenylpyrrole derivatives | DAIICHI SANKYO CO LTD | 2014-05-21 | — | — | CN | disclosed |
| EP-2239253-B1 | NOVEL PHENYLPYRROLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-8415359-B2 | Phenylpyrrole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-09 | — | — | US | disclosed |
| EP-2010520-B1 | HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PROD INC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2010520-B1 | HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PROD INC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2463283-A1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | Pfizer Products Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2463283-A1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | Pfizer Products Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8119624-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC. (US) | 2012-02-21 | — | — | US | disclosed |
| WO-2007017649-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2006125958-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
| EP-1718624-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006040528-A1 | PHENOXY BENZAMIDE COMPOUNDS WITH UTILITY IN THE TREATMENT OF TYPE 2 DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040528-A1 | PHENOXY BENZAMIDE COMPOUNDS WITH UTILITY IN THE TREATMENT OF TYPE 2 DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040529-A1 | BENZAMIDE DERIVATIVES THAT ACT UPON THE GLUCOKINASE ENZYME | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006040529-A1 | BENZAMIDE DERIVATIVES THAT ACT UPON THE GLUCOKINASE ENZYME | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005121110-A1 | HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005080359-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINAE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005080359-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINAE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |